

lifesciences

Life sciences leaders turn to Hale and Dorr for cutting-edge legal counsel and business advice. For over four decades, we have represented life sciences clients in landmark alliances, public offerings and mergers and acquisitions, as well as critical patent litigation.

1970s > 1980s > 1990s > 2003 >>

DIAGNOSTICS

LABORATORY SERVICES

PHARMACEUTICALS

MEDICAL DEVICES

HEALTHCARE SERVICES

BIOTECH

LIFE SCIENCES

MERGERS AND ACQUISITIONS

 has sold EDIX to TOTAL eMED \$64,000,000 June 2003	 has sold its excipient business to JOSEF RETTENMAIER HOLDING \$41,750,000 February 2003	 has merged with RIBOPHARMA Undisclosed July 2003	 has merged with GENVEC \$61,600,000 August 2003	 has sold the worldwide rights to PhosLo® (calcium acetate) to NABI PHARMACEUTICALS \$101,000,000 August 2003	 acquisition of 51% interest by NOVARTIS \$225,000,000 May 2003
---	---	---	---	--	---

PUBLIC OFFERINGS












 Rule 144A Placement of 0% Convertible Senior Subordinated Notes \$750,000,000 Counsel to Issuer December 2003	 Initial Public Offering of Common Stock \$52,500,000 Counsel to Underwriters October 2003	 Initial Public Offering of Common Stock \$61,380,000 Counsel to Issuer November 2003	 Follow-On Offering of Common Stock \$69,675,000 Counsel to Underwriters August 2003	 Follow-On Offering of Common Stock \$49,350,000 Counsel to Underwriters July 2003	 Follow-On Offering of Common Stock \$97,952,400 Counsel to Issuer March 2003
 Follow-On Offering of Common Stock \$90,000,000 Counsel to Underwriters October 2003	 Rule 144A Placement of 3.00% Convertible Senior Debentures \$275,000,000 Counsel to Issuer June 2003	 Follow-On Offering of Common Stock \$20,000,000 Counsel to Issuer October 2003	 Follow-On Offering of Common Stock \$20,500,000 Counsel to Issuer November 2003	 Follow-On Offering of Common Stock \$86,250,000 Counsel to Issuer August 2003	

STRATEGIC ALLIANCES AND COLLABORATIONS

 Collaboration with Genentech for the joint research and development of a Biogen protein therapeutic	 Agreement with Ortho Biotech to collaborate on the commercialization and continued clinical development of VELCADE cancer therapy	 IP asset sale and cross license with Cell Genesys as part of global alliance	 Collaboration agreement with Novartis to jointly develop and commercialize Idenix's core antiviral drug candidates	 Licensing advice on key biotechnology collaborations	 Distribution and supply agreement with Johnson & Johnson Wound Management for Quixil fibrin sealant product
---	--	---	---	--	---

VENTURE FINANCINGS

 Alliance with MedImmune to co-develop biologic products to treat severe inflammatory diseases	 Collaboration with Bayer HealthCare to identify pharmacogenomic markers of drug safety and efficacy	 License of electrochemiluminescent technologies to Roche Diagnostics	 Cancer therapeutic collaboration with Genentech	 Collaboration with Genzyme to develop and commercialize enzyme replacement therapy to treat Hunter syndrome in Asia	
 Collaboration agreement with Pfizer to jointly develop and commercialize ophthalmic products for the treatment of blindness	 Participation in international HapMap project	 Exclusive license of Torrey Mesa Research Institute IP to Diversa	 Feasibility, development and commercial supply agreement	 Collaboration and license agreement to provide Amgen with access to Infinity's proprietary small molecules for drug development	 Collaboration agreement with Merck to identify targets for the development of small molecule oncology agents

 \$42,700,000 Second Round July 2003	 \$12,000,000 First Round March 2003	 \$56,000,000 Second Round October 2003	 \$25,000,000 Strategic Investment by Pfizer February 2003	 \$24,600,000 Second Round July 2003	
 \$18,875,000 Second Round November 2003	 \$10,000,000 Third Round December 2003	 \$12,200,000 First Round November 2003	 \$19,000,000 Second Round May 2003	 \$13,400,000 Third Round February 2003	 \$25,000,000 Strategic Investment by Amgen December 2003

Hale and Dorr > >> Counsel of choice to life sciences leaders...from biotech to medical devices.

Boston

617 526 6000

London

44 20 7645 2400

Munich

49 89 24 213 0

New York

212 937 7200

Oxford

44 1235 823 000

Princeton

609 750 7600

Reston

703 654 7000

Waltham

781 966 2000

Washington

202 942 8400

Hale and Dorr LLP is a Massachusetts limited liability partnership. Our London and Oxford offices are operated under a Delaware limited liability partnership.

www.InternetAlerts.net

Enroll here to receive Hale and Dorr's brief and useful email alerts on a wide range of topics of interest to businesses and technology companies.

